共 50 条
Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
被引:3
|作者:
Dulai, Parambir S.
[1
]
Siegel, Corey A.
[2
]
机构:
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
关键词:
Crohn's disease;
ulcerative colitis;
risk;
adverse events;
inflammatory bowel disease;
infections;
NONMELANOMA SKIN-CANCER;
FACTOR-ALPHA ANTAGONISTS;
CROHNS-DISEASE;
INCREASED RISK;
HEPATITIS-B;
CLOSTRIDIUM-DIFFICILE;
COMBINATION THERAPY;
OPPORTUNISTIC INFECTIONS;
MAINTENANCE THERAPY;
RECEIVE THIOPURINES;
D O I:
10.2174/1389450118666170525114939
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
引用
收藏
页码:740 / 747
页数:8
相关论文